Page 118 - Read Online

Page 4 of 10 Simsek et al. Hepatoma Res 2020;6:11 I http://dx.doi.org/10.20517/2394-5079.2019.51

Table 1. Characteristics of the study population
Variable n = 26
Clinical features
Male sex, n (%) 23 (88.5%)
Age (years) 58.9 (6.8)
Ethnicity, n (%)
White 17 (65.4%)
African American 7 (27.0%)
Asian 2 (7.6%)
Etiology
HCV 13 (50%)
HBV 3 (11.5%)
ALD 2 (7.7%)
NAFLD 1 (3.9%)
HCV/ALD 6 (23%)
Other 1 (3.9%)
Explant pathology
Number of lesions, n (%)
1 9 (34.6%)
2 3 (11.5%)
3 3 (11.5%)
> 4 11 (42.4%)
Largest lesion (cm) 4.3 (3.8)
Tumor location, n (%)
Right lobe 13 (50%)
Left lobe 1 (3.9%)
Multi-lobar 12 (46.1%)
Tumor differentiation, n (%)
Well 0 (0%)
Moderate 14 (53.8%)
Poor 11 (42.3%)
Unknown 1 (3.9%)
Microvascular invasion, n (%)
Yes 19 (73.1%)
No 6 (23%)
Bile duct invasion 1 (3.9%)
Total number of loco-regional therapies, n (%)
0 9 (34.6%)
1 9 (34.6%)
2 5 (19.2%)
> 2 3 (11.6%)
Patients with viable tumor, n (%)
Yes 25 (96.2%)
No 1 (3.8%)
Within Milan, n (%)
Yes 10 (38.4%)
No 16 (61.6%)
Downstaged to Milan, n (%) 4 (15.4%)
Within UCSF, n (%)
Yes 11 (42.3%)
No 15 (57.7%)
Downstaged to UCSF, n (%) 3 (11.5%)
Laboratory
Pre-LT AFP (ng/mL) 27,578 (133,183)
Post-LT AFP (ng/mL) 23,586 (81,707)
MELD 13 (7)
9
WBC (10 /L) 6 (2.2)
Hgb (g/dL) 12.9 (2.7)
MCV (fL) 91 (6)
3
PLT (10 /μL) 116 (67)
BUN (mg/dL) 15 (6)
Creatinine (mg/dL) 1.1 (0.6)
TP (g/dL) 7.2 (0.8)
Alb (g/dL) 3.6 (0.7)
ALP (U/L) 141 (58)
AST (U/L) 109 (167)
ALT (U/L) 71 (122)
T.Bili (mg/dL) 2.2 (2.4)
PT (sec) 14 (4.1)
INR 1.3 (0.4)
Clinical and pathological characteristics of the 26 recipients with hepatocellular carcinoma recurrence following liver transplant.
Quantitative data are expressed as mean and categorical variables are reported as percentages. AFP: alpha fetoprotein; ALD: alcoholic
liver disease; Alb: albumin; ALP: alkaline phosphatase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea
nitrogen; HBV: hepatitis B virus; HCV: hepatitis C virus; Hgb: hemoglobin; INR: international normalized ratio; LT: liver transplant; MCV:
mean corpuscular volume; MELD: model for end-stage liver disease; NAFLD: non-alcoholic fatty liver disease; PLT: platelet count; PT:
prothrombin time; TP: total protein; T.Bili: total bilirubin; UCSF: University of California San Francisco; WBC: white blood cell count